

BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JOINT STOCK COMPANY
(Incorporated in the Socialist Republic of Vietnam)

CONSOLIDATED FINANCIAL STATEMENTS
THIRD QUARTER OF 2025



TABLE OF CONTENTS

<u>CONTENTS</u>	<u>PAGE(S)</u>
BOARDS OF DIRECTORS AND MANAGEMENT INTRODUCTION	1
CONSOLIDATED BALANCE SHEET	2 - 3
CONSOLIDATED INCOME STATEMENT	4
CONSOLIDATED CASH FLOW STATEMENT	5
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	6 - 20

THE BOARDS OF DIRECTORS AND MANAGEMENT:

The members of the Boards of Directors and Management of the Company during the year and to the date of this report are as follows:

Board of Directors

Mr Ta Nam Binh	Chairman
Mr Nguyen Tien Hai	Member
Ms Pham Thi Thanh Huong	Member
Mr Nguyen Ngoc Dung	Member
Mr Truong Thanh Liem	Member
Ms Nguyen Thi Minh Giang	Member
Mr Phan Tan Thu	Member

Board of Management

Ms Pham Thi Thanh Huong	General Director
Mr Huynh Ngoc Oanh	Deputy General Director (resigned on 01 January 2025)
Mr Nguyen Ngoc Dung	Deputy General Director
Ms Banh Thi Ngoc Quynh	Deputy General Director

CONSOLIDATED BALANCE SHEET
As at 30 September 2025

Unit: VND

ASSETS	Code	Notes	As of September 30, 2025	As of January 01, 2025
A CURRENT ASSETS	100		1,426,722,645,811	1,476,280,617,777
I Cash and cash equivalents	110	4	219,990,837,081	314,198,731,825
1. Cash	111		37,990,837,081	56,698,731,825
2. Cash equivalents	112		182,000,000,000	257,500,000,000
II Short-term investments	120		312,201,393,300	124,421,158,600
1. Held-for-trading securities	121		1,393,300	1,393,300
2. Held-to-maturity investments	123	5	312,200,000,000	124,419,765,300
III Current accounts receivable	130		494,702,766,988	520,222,627,983
1. Short-term trade receivables	131	6	492,503,170,785	504,877,324,434
2. Short-term advances to suppliers	132	7	55,143,119,728	76,498,728,383
5. Other short-term receivables	136	8	11,391,728,474	6,918,534,026
6. Provision for doubtful debts	137		(64,335,251,999)	(68,071,958,860)
IV Inventories	140		379,458,440,065	505,380,962,218
1. Inventories	141	9	403,124,847,806	532,336,906,627
2. Provision for obsolete inventories	149	9	(23,666,407,741)	(26,955,944,409)
V Other current assets	150		20,369,208,377	12,057,137,151
1. Short-term prepaid expenses	151	10	8,819,159,675	8,653,554,344
2. Value-added tax deductible	152		11,205,641,794	1,895,670,328
3. Tax and other receivables from the State	153	17	344,406,908	1,507,912,479
B NON-CURRENT ASSETS	200		1,004,854,883,806	787,925,914,939
I Fixed assets	220		361,881,981,346	337,549,679,184
1. Tangible fixed assets	221	11	279,332,502,074	280,725,745,444
Cost	222		848,736,939,460	810,661,849,768
Accumulated depreciation	223		(569,404,437,386)	(529,936,104,324)
2. Intangible fixed assets	227	12	82,549,479,272	56,823,933,740
Cost	228		103,144,669,688	76,110,993,392
Accumulated amortisation	229		(20,595,190,416)	(19,287,059,652)
II Long term assets in progress	240		441,973,868,705	233,459,463,621
1. Long-term construction in progress	242	13	441,973,868,705	233,459,463,621
III Long-term investments	250		148,444,652,525	164,241,726,585
2. Investments in associates	252		146,931,117,554	162,728,191,614
3. Investment in other entities	253	14	3,513,534,971	3,513,534,971
4. provision for long term investment devaluation	254	14	(2,000,000,000)	(2,000,000,000)
IV Other long-term assets	260		52,554,381,230	52,675,045,549
1. Long-term prepaid expenses	261	10	38,759,188,942	39,382,942,604
2. Deferred tax assets	262		13,795,192,288	13,292,102,945
TOTAL ASSETS	270		2,431,577,529,617	2,264,206,532,716

0023
TY
TÂN
THIẾT B
DINH
HAR)
IA LAI

CONSOLIDATED BALANCE SHEET (Continued)
As at 30 September 2025

Unit: VND

RESOURCES	Code	Notes	As of September 30, 2025	As of January 01, 2025
C LIABILITIES	300		722,417,873,111	603,065,716,999
I Current liabilities	310		530,976,743,937	460,154,613,654
1. Short-term trade payables	311	15	153,584,965,332	160,802,900,081
2. Short-term advances from customers	312	16	13,745,500,225	15,976,752,341
3. Statutory obligations	313	17	42,806,353,470	27,372,531,041
4. Payables to employees	314		97,608,884,438	78,337,451,082
5. Short-term accrued expenses	315	19	25,545,885,261	19,823,557,873
6. Other short-term payables	319	18	4,977,351,322	8,681,086,654
7. Short-term loan and finance lease	320	20	98,218,278,484	35,913,500,637
9. Bonus and welfare fund	322	21	94,489,525,405	113,246,833,945
II Non-current liabilities	330		191,441,129,174	142,911,103,345
1. Long-term loans and finance lease obligations	338	20	80,301,250,000	28,000,000,000
2. Other long-term provisions	342		7,205,720,125	7,267,083,725
3. Scientific and technological development fund	343	22	103,934,159,049	107,644,019,620
D OWNERS' EQUITY	400		1,709,159,656,506	1,661,140,815,717
I Capital	410		1,707,541,997,450	1,658,732,981,612
1. Contributed charter capital/Share capital	411	23	945,293,470,000	935,938,470,000
- Shares with voting rights	411A		945,293,470,000	935,938,470,000
2. Share premium	412		20,921,442,000	20,921,442,000
3. Treasury shares	415		(1,952,796,558)	(1,952,796,558)
4. Foreign exchange differences reserve	417		1,170,735,727	4,790,551,103
5. Investment and development fund	418		201,686,964,998	201,686,964,998
6. Undistributed earnings/Accumulated losses	421		540,422,181,283	497,348,350,069
- Undistributed earnings/Accumulated losses up to prior year-end	421A		309,204,388,812	288,210,068,687
- Net profit/loss after tax this period	421B		231,217,792,471	209,138,281,382
II Other funds	430		1,617,659,056	2,407,834,105
1. Subsidised fund	431		(118,414,839)	38,936,237
2. Fund for fixed assets in use	432		1,736,073,895	2,368,897,868
TOTAL LIABILITIES AND OWNERS' EQUITY	440		2,431,577,529,617	2,264,206,532,716




Pham Thi Thanh May
Preparer



Do Huy Phuong
Chief Accountant




Pham Thi Thanh Huong
General Director
October, 27th, 2025

CONSOLIDATED INCOME STATEMENT
THIRD QUARTER OF 2025

Unit: VND

Numerical order	Items	Code	Notes	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
1.	Revenue from sale of goods and rendering of services	1		457,036,601,492	451,184,764,996	1,409,576,627,478	1,301,833,622,272
2.	Deductions	2		17,338,229,305	18,366,435,962	54,296,185,249	52,186,139,756
3.	Net revenue from sale of goods and rendering of services (10 = 1 - 2)	10	25	439,698,372,187	432,818,329,034	1,355,280,442,229	1,249,647,482,516
4.	Cost of goods sold and services rendered	11	26	252,404,294,273	218,374,162,391	697,363,708,152	633,557,883,132
5.	Gross profit/(loss) from sale of goods and rendering of services	20		187,294,077,914	214,444,166,643	657,916,734,077	616,089,599,384
6.	Finance income	21	28	9,088,076,486	3,369,164,852	18,296,240,673	8,730,895,218
7.	Finance expenses	22	29	4,090,480,901	4,742,823,946	10,786,960,734	12,731,275,167
	- In which: Interest expense	23		1,339,973,239	817,753,000	2,844,596,315	3,071,197,275
8.	Shares of profit/(loss) of associates, joint-ventures	24		(8,441,185,109)	6,952,120,989	3,149,956,573	13,446,997,281
9.	Selling expenses	25	30	88,096,365,357	110,617,547,889	313,830,362,879	303,980,245,252
10.	General and administrative expenses	26	31	23,571,257,861	20,969,514,590	77,822,880,183	66,885,451,083
11.	Operating profit/(loss) (30=20+(21-22)+24-(25+26))	30		72,182,865,172	88,435,566,059	276,922,727,527	254,670,520,381
12.	Other income	31		110,901,386	278,678,337	315,927,542	342,027,226
13.	Other expenses	32		825,721,183	323,869,654	3,124,197,569	679,382,895
14.	Other profit/ (loss) (40=31-32)	40		(714,819,797)	(45,191,317)	(2,808,270,027)	(337,355,669)
15.	Accounting profit/ (loss) before tax (50=30+40)	50		71,468,045,375	88,390,374,742	274,114,457,500	254,333,164,712
16.	Current corporate income tax expense	51	32	11,910,845,417	13,478,655,299	43,362,755,692	40,285,244,758
17.	Deferred income tax income/ (expense)	52	32	(351,835,610)	(109,080,084)	(503,089,343)	(511,963,963)
18.	Net profit/ (loss) after tax (60=50-51-52)	60		59,909,035,568	75,020,799,527	231,254,791,151	214,559,883,917



Pham Thi Thanh May
Preparer



Do Huy Phuong
Chief Accountant



Pham Thi Thanh Huong
General Director
October, 27th, 2025

CONSOLIDATED CASH FLOW STATEMENT
NINE MONTHS OF 2025

Unit: VND

Code	Items	Accumulated nine months of 2025	Accumulated nine months of 2024
I	CASH FLOWS FROM OPERATING ACTIVITIES		
1	<i>Profit/(loss) before tax</i>	274,114,457,500	254,333,164,712
	<i>Adjustments for:</i>		
2	Depreciation of tangible fixed assets and investment properties and amortisation of intangible fixed assets	38,349,338,641	35,918,963,500
3	Provisions/(reversal of provision)	(7,087,607,129)	484,055,655
4	Foreign exchange (gains)/losses arising from revaluation of monetary accounts denominated in monetary currency	(171,678,337)	128,539,564
5	(Profits)/losses from investing activities	(16,721,897,520)	(20,682,872,968)
6	Interest expenses	2,844,596,315	3,071,197,275
8	Operating profit/(loss) before changes in working capital	291,327,209,470	273,253,047,738
9	(Increase)/decrease in receivables	3,954,894,968	5,493,682,108
10	(Increase)/decrease in inventories	129,212,058,821	4,444,342,041
11	Increase/(decrease) in payables (other than interest, corporate income tax)	32,084,053,629	(36,089,882,326)
12	(Increase)/decrease in prepaid expenses	458,148,331	(789,842,595)
14	Interest paid	(2,945,089,315)	(3,203,142,275)
15	Corporate income tax paid	(31,823,079,112)	(38,091,578,137)
16	Other cash inflows from operating activities	1,248,815,372	402,643,592
17	Other cash outflows for operating activities	(21,823,163,819)	(3,045,693,626)
20	Net cash from/(used in) operating activities	401,693,848,345	202,373,576,520
II	CASH FLOWS FROM INVESTING ACTIVITIES		
21	Purchase and construction of fixed assets and other long-term assets	(273,038,208,185)	(112,791,028,826)
23	Loans to other entities and payments for purchase of debt instruments of other entities	(206,409,222,001)	(110,010,045,308)
24	Collections from borrowers and proceeds from sale of debt instruments of other entities	32,919,765,300	218,693,126,650
27	Interest and dividends received	12,192,735,602	7,044,135,578
30	Net cash from/(used in) investing activities	(434,334,929,284)	2,936,188,094
III	CASH FLOWS FROM FINANCING ACTIVITIES		
31	Capital contribution and issuance of shares	9,355,000,000	-
33	Drawdown of borrowings	168,970,230,767	40,466,201,000
34	Repayment of borrowings	(54,364,202,920)	(71,733,320,497)
36	Dividends paid/Profit distributed	(185,523,560,475)	(9,933,200)
40	Net cash flows from/(used in) financing activities	(61,562,532,628)	(31,277,052,697)
50	Net increase/(decrease) in cash for the year	(94,203,613,567)	174,032,711,917
60	Cash [and cash equivalents] at beginning of year	314,198,731,825	87,837,172,191
61	Impact of exchange rate fluctuation	(4,281,177)	(22,086,943)
70	Cash [and cash equivalents] at end of year	219,990,837,081	261,847,797,165



Pham Thi Thanh May
Preparer



Do Huy Phuong
Chief Accountant



Pham Thi Thanh Huong
General Director
October, 27th, 2025

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

These notes are an integral part of and should be read in conjunction with the accompanying consolidated financial statements.

1. CORPORATE INFORMATION

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) ("the Company") was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QĐ-UBND on 23 June 2010 and the first Enterprise Registration Certificate ("ERC") No. 4100259564 issued by Department of Planning and Investment ("DPI") of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14th amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares were listed on the Ho Chi Minh City Stock Exchange ("HOSE") with trading code as DBD in accordance with License No. 185/QĐ-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Group are manufacturing and trading in pharmaceutical products and medical equipment.

The Group's normal course of business cycle is 12 months.

The Company's registered head office is located at 498 Nguyen Thai Hoc Street, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has seventeen (17) branches located at other province/cities within Vietnam.

The number of the Group's employees as at 30 September 2025 was 1,353 employees.

Corporate structure

As at 30 September 2025, the Group's corporate structure included two (2) subsidiaries and an associate. Details are as follows:

Name	Head office	Business activities	30 September 2025 and 31 December 2024	
			Ownership (%)	Voting rights (%)
Subsidiaries				
(1) Bidiphar Trading Company Limited	Gia Lai Province	Wholesale and retail sale of medicines, medicinal herbs, medical equipment	100.00	100.00
(2) Bidiphar Organic Medicine Limited Company	Gia Lai Province	Production of medicines, medicinal chemicals and medicinal herbs	100.00	100.00
Associate				
(1) Bidiphar Rubber Joint Stock Company	Gia Lai Province	Planting, mining, processing and trading rubber latex	33.58	33.58

2. BASIS OF PREPARATION

2.1 *Accounting standards and system*

The consolidated financial statements of the Group expressed in Vietnam dong ("VND"), are prepared in accordance with the Vietnamese Enterprise Accounting System and Vietnamese Accounting Standard No. 27 - Financial Reporting and other Vietnamese Accounting Standards issued by the Ministry of Finance as per:

- Decision No. 149/2001/QĐ-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- Decision No. 165/2002/QĐ-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- Decision No. 234/2003/QĐ-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- Decision No. 12/2005/QĐ-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- Decision No. 100/2005/QĐ-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying consolidated financial statements, including their utilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the consolidated financial position and consolidated results of operations and consolidated cash flows in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

2.2 *Applied accounting documentation system*

The Group's applied accounting documentation system is the Computerised based.

2.3 *Fiscal year*

The Group's fiscal year applicable for the preparation of its consolidated financial statements starts on 1 January and ends on 31 December.

2.4 *Accounting currency*

The consolidated financial statements are prepared in VND which is also the Group's accounting currency.

2.5 *Basic of consolidation*

The consolidated financial statements comprise the separate financial statements of the Company and its subsidiaries for the third quarter ended 30 September 2025.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtains control, and continued to be consolidated until the date that such control ceases.

The financial statements of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies.

All intra-company balances, income and expenses and unrealized gains or losses resulted from intra-company transactions are eliminated in full.

Non-controlling interests represent the portion of profit or loss and net assets not held by the Group and are presented separately in the consolidated income statement and within equity in the consolidated balance sheet.

Impact of change in the ownership interest of a subsidiary, without a loss of control, is recorded in undistributed earnings.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 *Cash and cash equivalents*

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of changes in value.

3.2 *Inventories*

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value. Net realisable value represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The perpetual method is used to record inventories, which are valued as follows:

Raw materials, tool and supplies and merchandise	- actual cost on a weighted average basis.
Work-in-process and finished goods	- cost of finished goods and work-in-process on a weighted average basis.

Provision for obsolete inventories

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, merchandise and other inventories owned by the Group, based on appropriate evidence of impairment available at the balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the consolidated income statement. When inventories are expired, obsolescence, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the consolidated income statement.

3.3 *Receivables*

Receivables are presented in the consolidated balance sheet at the carrying amounts due from customers and other debtors, after the provision for doubtful receivables.

The provision for doubtful receivables represents amounts of outstanding receivables at the balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administrative expense in the consolidated income statement. When bad debts are determined as unrecoverable and accountant written off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the consolidated income statement.

3.4 *Tangible fixed assets*

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use. Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the consolidated income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

3.5 *Intangible fixed assets*

Intangible fixed assets are stated at cost less accumulated amortization.

The cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use. Expenditures for additions, improvements are

added to the carrying amount of the assets and other expenditures are charged to the consolidated income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

Land used rights

Land use rights are recorded as intangible fixed assets representing the value of the rights to use the lands acquired by the Group. The advance payment for land rental, of which the land lease contracts, and Land use rights certificate being issued, are recorded as intangible fixed asset according to Circular No. 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013 guiding the management, use and depreciation of fixed assets ("Circular 45").

The useful life of land use rights are assessed as either definite or indefinite. Accordingly, the land use rights with definite useful life representing the land lease are amortized over the lease term while the land use rights with indefinite useful lives is not amortized.

3.6 Depreciation and amortization

Depreciation of tangible fixed assets and amortization of intangible fixed assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	4 - 43 years
Machinery and equipment	4 - 12 years
Means of transportation	4 - 10 years
Office equipment	4 - 10 years
Land use rights	50 years
Computer software	4 - 10 years

3.7 Construction in progress

Construction in progress represents fixed assets under construction and is stated at cost. This includes costs of construction, installation of equipment and other direct costs. Construction in progress is not depreciated until such time as the relevant assets are completed and put into operation.

3.8 Borrowing costs

Borrowing costs consist of interest and other costs that the Group incurs in connection with the borrowing of funds.

3.9 Leased assets

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

A lease is classified as a finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership of the asset to the lessee. All other leases are classified as operating leases.

Where the Group is the lessee

Rentals under operating leases are charged to the consolidated income statement on a straight-line basis over the term of the lease.

3.10 Prepaid expenses

Prepaid expenses are reported as short-term or long-term prepaid expenses on the consolidated balance sheet and amortized over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

100
G TY
PHÂN
ANG TH
BÌNH D
DIPHA
H GI

3.11 Accrual for severance pay

The severance pay to employee is accrued at the end of each reporting year for employees who have been worked for more than 12 months at the Group. The accrued amount is calculated at the rate of one-half of the average monthly salary for each year of service qualified for severance pay in accordance with the Labour Code and related implementing guidance. The average monthly salary used in this calculation will be revised at the end of each reporting period following the average monthly salary of the 6-month period up to the reporting date. Any increase or decrease to the accrued amount other than actual payment to employee will be taken to the consolidated income statement.

This accrued severance pay is used to settle the termination allowance to be paid to employee upon termination of their labour contract following Article 46 of the Labour Code.

3.12 Business combinations

Business combinations are accounted for using the purchase method. The cost of a business combination is measured as the fair value of assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange plus any costs directly attributable to the business combination. Identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured initially at fair values at the date of business combination.

3.13 Investments

Investment in an associate

The Group's investment in its associate is accounted for using the equity method of accounting. An associate is an entity in which the Group has significant influence that is neither subsidiaries nor joint ventures. The Group generally deems they have significant influence if they have over 20% of the voting rights.

Under the equity method, the investment is carried in the consolidated balance sheet at cost plus post-acquisition changes in the Group's share of net assets of the associates. Goodwill arising on acquisition of the associate is included in the carrying amount of the investment. Goodwill is not amortized and subject to annual review for impairment. The consolidated income statement reflects the share of the post-acquisition results of operation of the associate.

The share of post-acquisition profit (loss) of the associate is presented on face of the consolidated income statement and its share of post-acquisition movements in reserves is recognized in reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Dividend/profit sharing receivable from associate reduces the carrying amount of the investment.

The financial statements of the associate are prepared for the same reporting period and use the same accounting policies as the Group. Where necessary, adjustments are made to bring the accounting policies in line with those of the Group.

Held-for-trading securities and investments in other entities

Held-for-trading securities and investments in other entities are stated at their acquisition costs.

Provision of the investments

Provision for diminution in value of the investment is made when there are reliable evidences of the diminution in value of those investments at the balance sheet date.

Increases or decreases to the provision balance are recorded as finance expense in the consolidated income statement.

Held-to-maturity investments

Held-to-maturity investments are stated at their acquisition costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognized as expense in the consolidated financial statements and deducted against the value of such investments.

3.14 Payables and accruals

Payables and accruals are recognized for amounts to be paid in the future for goods and services received, whether or not billed to the Group.



3.15 Foreign currency transactions

Transactions in currencies other than the Group's reporting currency of VND are recorded at the actual transaction exchange rates at transaction dates which are determined as follows:

- Transactions resulting in receivables are recorded at the buying exchange rates of the commercial banks designated for collection; and
- Transactions resulting in liabilities are recorded at the selling exchange rates of the commercial banks designated for payment.

At the end of the period, monetary balances denominated in foreign currencies are translated at the actual transaction exchange rates at the balance sheet dates which are determined as follows:

- monetary assets are translated at buying exchange rate of the commercial bank where the Group conducts transactions regularly; and
- monetary liabilities are translated at selling exchange rate of the commercial bank where the Group conducts transactions regularly.

All foreign exchange differences incurred are taken to the consolidated income statement.

3.16 Treasury shares

Own equity instruments which are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in profit or loss upon purchase, sale, re-issue or cancellation of the Group's own equity instruments.

3.17 Appropriation of net profits

Net profit after tax (excluding negative goodwill arising from a bargain purchase) is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Group maintains the following reserve funds which are appropriated from the Group's net profit as proposed by the Board of Directors and subject to approval by shareholders at the annual general meeting:

Investment and development fund

This fund is set aside for use in the Group's expansion of its operation or of in-depth investments.

Bonus and welfare fund

This fund is comprised of bonus, welfare fund for employees and bonus fund for the management, which is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits. This fund is presented as a liability on the consolidated balance sheet.

Dividends

Dividends proposed by the Group's Board of Directors are classified as an allocation of undistributed earnings within the equity section of the consolidated balance sheet, until they have been approved by the Group's shareholders at the Annual General Meeting. When these dividends have been approved by the shareholders and declared, they are recognized as a liability in the consolidated balance sheet.

3.18 Earnings per share

Basic earnings per share amount is computed by dividing net profit attributable to ordinary equity holders of the Group (after adjusting for the bonus and welfare fund) by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net profit after tax attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

3.19 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognized:

Sale of goods

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

Rendering of services

Revenue is recognized when the services have been performed and completed.

Interest

Revenue is recognized as the interest accrues (taking into account the effective yield on the asset) unless collectability is in doubt.

3.20 Taxation

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be paid to or recovered from the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the balance sheet date.

Current income tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the current deferred income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Group to set off current income tax assets against current income tax liabilities and when the Group intend to settle its current income tax assets and liabilities on a net basis.

Deferred tax

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purpose.

Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profits will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Previously unrecognized deferred tax assets are re-assessed at each balance sheet date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized, or the liability is settled based on tax rates and tax laws that have been enacted at the balance sheet date.

Deferred tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the deferred tax is also dealt with in the equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Group to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on the same taxable entity or when the Group intends either to settle current tax liabilities and assets on a net basis or to realize the assets and settle the liabilities simultaneously, in each future year in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

3.21 Segment reporting

A segment is a component determined separately by the Group which is engaged in providing products or related services (business segment) or providing products or services in a particular economic environment (geographical segment), that is subject to risks and returns that are different from those of other segments. As the Company's revenue and profit are derived mainly from manufacturing and trading pharmaceutical products in Vietnam while other sources of revenue are not material as a whole, management accordingly believes that the Group operates in a sole business segment of manufacturing and trading pharmaceutical products within a single geographical segment. Therefore, no further segmental information is required to be presented.

3.22 Related parties

Parties are considered to be related parties of the Group if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Group and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including close members of the family of any such individual.

4. CASH AND CASH EQUIVALENTS:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Cash on hand	1,260,088,991	1,496,871,788
Cash in banks	36,730,748,090	55,201,860,037
Cash equivalent	182,000,000,000	257,500,000,000
	<u>219,990,837,081</u>	<u>314,198,731,825</u>

(*) Cash equivalents represent term deposits with original term of less than or equal to 3 months at commercial banks.

5. SHORT -TEARM HELD-TO-MATURITY INVESTMENTS:

Held-to-maturity investments represent term deposits at commercial banks with original terms of more than three months and remaining terms of less than one year which earn interest at rate from 3.9% per annum to 5.8% per annum

6. SHORT-TERM TRADE RECEIVABLES:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Hanoi Cancer Hospital	19,482,921,150	21,539,000,771
Cancer Hospital, Facility 1, HCM	12,624,117,020	16,412,915,740
Gia Lai Provincial General Hospital	13,002,197,633	14,119,090,727
Cho Ray Hospital	12,605,556,306	11,290,598,256
Dong Nam Technical Investment Company	45,131,856,249	45,131,856,249
Others	389,656,522,427	396,383,862,691
	<u>492,503,170,785</u>	<u>504,877,324,434</u>

7. SHORT-TERM ADVANCES TO SUPPLIERS:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Dong A Mechanical and Refrigeration Joint Stock Company	7,832,429,554	267,979,046
Viet Son Technical Company	4,434,147,686	-
Bach Khoa Limited Liability Company	4,720,000,000	-
Binh Dinh Construction Limited Liability Company	2,632,635,332	-
Tofflon Science	8,652,150,000	36,272,301,000
Others	26,871,757,156	39,958,448,337
	<u>55,143,119,728</u>	<u>76,498,728,383</u>

8. OTHER SHORT-TERM RECEIVABLES:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Advance to employees	4,062,514,931	932,928,777
short term deposit	98,189,846	106,825,952
Interest receivable	3,847,767,672	2,468,562,327
Others	3,383,256,025	3,410,216,970
	<u>11,391,728,474</u>	<u>6,918,534,026</u>

9. INVENTORIES:

	As of September 30, 2025		As of January 01, 2025	
	Cost	Provision	Cost	Provision
	VND	VND	VND	VND
Goods in transit	-	-	40,395,223,790	
Raw materials	242,360,274,366	(20,331,067,561)	269,060,649,045	(21,907,801,829)
Tools and equipment	1,664,839,589	-	1,678,354,169	
Work in progress	11,467,316,691	-	28,947,218,521	
Finished goods	142,760,259,632	(1,518,060,050)	184,478,440,062	(3,124,185,961)
Merchandise goods	4,872,157,528	(1,817,280,130)	7,777,021,040	(1,923,956,619)
	<u>403,124,847,806</u>	<u>(23,666,407,741)</u>	<u>532,336,906,627</u>	<u>(26,955,944,409)</u>

10. PREPAYMENTS:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
a. Short term		
Tools and supplies	1,616,296,840	2,538,609,158
Maintenance and repair	4,258,020,441	4,016,797,362
Rental	270,000,000	240,000,000
Others	2,674,842,394	1,858,147,824
	<u>8,819,159,675</u>	<u>8,653,554,344</u>
b. Long term		
Land rental	29,581,172,266	30,248,346,672
Tools and supplies	2,512,817,120	3,222,178,615
Maintenance and repair	5,559,772,562	5,034,904,647
Others	1,105,426,994	877,512,670
	<u>38,759,188,942</u>	<u>39,382,942,604</u>

11. TANGIBLE FIXED ASSETS:

	Buildings and structure VND	Machinery and equipment VND	Means of transportation VND	Office equipment VND	Total VND
Cost:					
As at 01 January 2025	232,539,286,649	507,610,407,434	51,052,125,034	19,460,030,651	810,661,849,768
	1,533,316,343	19,119,237,134	-	-	20,652,553,477
Construction in progress completed					
Newly purchases	-	13,808,468,871	-	3,906,936,552	17,715,405,423
Disposal	-	(250,596,481)	-	(42,272,727)	(292,869,208)
As at 30 September 2025	234,072,602,992	540,287,516,958	51,052,125,034	23,324,694,476	848,736,939,460
Accumulated depreciation:					
As at 01 January 2025	138,824,082,950	334,276,711,399	39,948,689,928	16,886,620,047	529,936,104,324
Depreciation for the period	11,834,201,881	25,214,872,459	1,685,462,641	1,026,665,289	39,761,202,270
Disposal	-	(250,596,481)	-	(42,272,727)	(292,869,208)
As at 30 September 2025	150,658,284,831	359,240,987,377	41,634,152,569	17,871,012,609	569,404,437,386
Net carrying amount:					
As at 01 January 2025	93,715,203,699	173,333,696,035	11,103,435,106	2,573,410,604	280,725,745,444
As at 30 September 2025	83,414,318,161	181,046,529,581	9,417,972,465	5,453,681,867	279,332,502,074

12. INTANGIBLE ASSETS:

	Land use rights VND	Computer software VND	Total VND
Cost:			
As at 01 January 2025	56,767,881,650	19,343,111,742	76,110,993,392
Newly purchases	-	1,457,965,000	1,457,965,000
Construction in progress completed	25,575,711,296	-	25,575,711,296
As at 30 September 2025	82,343,592,946	20,801,076,742	103,144,669,688
Accumulated depreciation:			
As at 01 January 2025	2,930,983,237	16,356,076,415	19,287,059,652
Depreciation for the period	170,672,912	1,137,457,852	1,308,130,764
As at 30 September 2025	3,101,656,149	17,493,534,267	20,595,190,416
Net carrying amount:			
As at 01 January 2025	53,836,898,413	2,987,035,327	56,823,933,740
As at 30 September 2025	79,241,936,797	3,307,542,475	82,549,479,272

13. CONSTRUCTION IN PROGRESS:

	As of September 30, 2025 VND	As of January 01, 2025 VND
Hi-tech pharmaceutical factory (Nhon Hoi)	407,215,735,280	158,721,743,664
Project in medicinal plants	1,373,137,367	675,840,234
Powder injection line	23,496,972,309	28,689,372,308
Ho Chi Minh Branch Office	-	24,924,000,000
Others	9,888,023,749	20,448,507,415
	441,973,868,705	233,459,463,621

14. EQUITY INVESTMENT IN OTHER ENTITIES:

	Ownership	Number of shares	As of September 30, 2025 and as of January 01, 2025	
			Cost	Provision
	%		VND	VND
Nghe An Pharmaceutical Medical Material and Equipment JSC	3.4	205,710	1,513,534,971	-
Thien Phuc JSC	10.0	200,000	2,000,000,000	2,000,000,000
			3,513,534,971	2,000,000,000

15. SHORT-TERM TRADE PAYABLES:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Mirih Hung M&C Joint Stock Company	8,273,490,582	8,718,730,960
Bach Khoa Limited Liability Company	19,798,912,702	-
Tofflon Science	27,459,131,654	3,020,202,000
Truking Technology Limited	12,089,579,550	3,113,579,550
Cheiron Pharma	3,879,880,050	2,005,478,250
Others	82,083,970,794	143,944,909,321
	153,584,965,332	160,802,900,081

16. SHORT-TERM ADVANCES FROM CUSTOMERS:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
VP-Pharma Pharmaceutical JSC	1,555,407,950	1,396,512,100
Sundial Pharma Joint Stock Company	4,220,832,026	3,444,824,049
Rexton JSC	1,200,340,200	847,350,000
Truong Phuc Company	1,044,177,301	-
Others	5,724,742,748	10,288,066,192
	13,745,500,225	15,976,752,341

17. TAXES AND OTHER RECEIVABLES FROM/PAYABLES TO THE STATE BUDGET:

	As of January 01, 2025	To be submitted in nine months of 2025	To be submitted in nine months of 2025	As of September 30, 2025
	VND	VND	VND	VND
Value-added tax ("VAT")	976,543,064	17,619,208,507	9,438,251,670	9,157,499,901
+Payable	976,543,064	17,619,208,507	9,438,251,670	9,157,499,901
+Receivable	-	-	-	-
VAT on imported goods	(1,350,975,545)	25,136,730,373	23,867,880,411	(82,125,583)
Import and Export Tax	-	441,871,049	441,871,049	-
Corporate income tax	19,564,487,839	43,362,755,692	31,823,079,112	31,104,164,419
+Payable	19,718,128,295	43,209,115,236	31,823,079,112	31,104,164,419
+Receivable	(153,640,456)	153,640,456	-	-
Personal income tax	2,949,010,433	24,527,157,873	26,297,672,108	1,178,496,198
+Payable	2,952,306,911	24,786,142,720	26,297,672,108	1,440,777,523
+Receivable	(3,296,478)	(258,984,847)	-	(262,281,325)

Others	3,725,552,771	4,989,384,022	7,611,025,166	1,103,911,627
	<u>25,864,618,562</u>	<u>116,077,107,516</u>	<u>99,479,779,516</u>	<u>42,461,946,562</u>
In which:				
Receivable	(1,507,912,479)			(344,406,908)
Payable	27,372,531,041			42,806,353,470

18. OTHER CURRENT PAYABLES:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Dividends payable to shareholders	1,705,442,350	121,478,825
Trade Union	821,762,502	280,371,412
Others	2,450,146,470	8,279,236,417
	<u>4,977,351,322</u>	<u>8,681,086,654</u>

19. SHORT-TERM ACCRUED EXPENSES:

	As of September 30, 2025	As of January 01, 2025
	VND	VND
Selling expenses	21,919,718,593	19,371,213,021
Others	3,626,166,668	452,344,852
	<u>25,545,885,261</u>	<u>19,823,557,873</u>

20. LOANS:

	As of January 01,2025	9 months of 2025		As of September 30, 2025
	VND	Increase VND	Decrease VND	VND
a.Short-term loan				
Loan from banks	19,913,500,637	104,668,980,767	42,364,202,920	82,218,278,484
+ Bank for Investment and Development of Vietnam (BIDV), Gia Lai Branch.	-	70,705,348,325	10,000,000,000	60,705,348,325
+ Joint Stock Commercial Bank for Foreign Trade Of Vietnam, Quy Nhon Branch	19,913,500,637	33,963,632,442	32,364,202,920	21,512,930,159
Current portion	<u>16,000,000,000</u>	<u>12,000,000,000</u>	<u>12,000,000,000</u>	<u>16,000,000,000</u>
	<u>35,913,500,637</u>	<u>116,668,980,767</u>	<u>54,364,202,920</u>	<u>98,218,278,484</u>
b.Non-current portion				
Gia Lai Development Investment Fund	<u>28,000,000,000</u>	<u>64,301,250,000</u>	<u>12,000,000,000</u>	<u>80,301,250,000</u>

21. BONUS AND WELFARE FUNDS:

	Bonus fund VND	Welfare fund VND	Bonus fund for management VND	Total VND
As of January 01,2025	35,444,876,372	61,744,636,563	16,057,321,010	113,246,833,945
Increase from profits	-	36,998,680	-	36,998,680
Used funds	(1,017,000,000)	(1,744,107,220)	(16,033,200,000)	(18,794,307,220)
As of September 30,2025	<u>34,427,876,372</u>	<u>60,037,528,023</u>	<u>24,121,010</u>	<u>94,489,525,405</u>

22. SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT FUND:

	Scientific and technological development fund	Scientific and technological development fund formed fixed assets	Total
	VND	VND	VND
As of January 01, 2025	88,177,085,243	19,466,934,377	107,644,019,620
Profit appropriation	15,000,000,000	-	15,000,000,000
Other Decrease	(16,622,690,151)	-	(16,622,690,151)
Depreciation charged to scientific and technological development fund	-	(2,087,170,420)	(2,087,170,420)
As of September 30, 2025	86,554,395,092	17,379,763,957	103,934,159,049

23. OWNER'S EQUITY:

	As of September 30, 2025			As of January 01, 2025		
	Number of shares	Ownership	VND	Number of shares	Ownership	VND
BinhDinh Development Investment Found	12,485,606	13.21	124,856,060,000	12,485,606	13.34	124,856,060,000
Other shareholders	82,003,656	86.75	820,036,560,000	81,068,156	86.61	810,681,560,000
Treasury shares	40,085	0.04	400,850,000	40,085	0.05	400,850,000
	94,529,347	100	945,293,470,000	93,593,847	100	935,938,470,000

24. OFF BALANCE SHEET ITEMS:

	As of September 30, 2025	As of January 01, 2025
Foreign currencies:		
United States dollar (USD)	32,921.09	2,596.70
Euro (EUR)	131.96	145.82

25. REVENUE FROM GOODS SOLD AND SERVICES RENDERED:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Gross revenues	457,036,601,492	451,184,764,996	1,409,576,627,478	1,301,833,622,272
Of which:				
Sales of pharmaceutical finished goods	436,652,663,889	434,012,185,903	1,362,288,007,533	1,256,363,899,620
Sales of pharmaceutical merchandises	7,648,793,806	11,702,946,700	26,001,195,218	25,489,214,758
Sales of medical supplies	1,175,478,488	1,018,900,148	3,235,527,990	6,086,161,861
Sales of materials, packaging, tools and supplies	3,504,331,614	4,315,224,030	9,909,707,727	12,756,854,493
Others	8,055,333,695	135,508,215	8,142,189,010	1,137,491,540
Less	17,338,229,305	18,366,435,962	54,296,185,249	52,186,139,756
Trade discounts	15,946,421,299	17,599,438,241	51,418,944,032	49,701,097,183
Sales returns	1,391,808,006	766,997,721	2,877,241,217	2,485,042,573
NET	439,698,372,187	432,818,329,034	1,355,280,442,229	1,249,647,482,516

26. COST OF GOODS SOLD AND SERVICES RENDERED:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Cost of pharmaceutical finished goods sold	235,782,563,335	203,133,057,038	658,447,175,246	594,896,308,258
Cost of pharmaceutical merchandises sold	7,313,029,053	11,184,017,724	24,830,249,704	24,334,050,788
Cost of medical supplies sold	1,051,674,932	899,581,517	2,803,336,536	5,570,886,212
Cost of materials, packaging, tools and supplies sold	2,525,538,287	3,083,933,033	5,525,832,482	8,179,658,615
Others	5,731,488,666	73,573,079	5,757,114,184	576,979,259
	<u>252,404,294,273</u>	<u>218,374,162,391</u>	<u>697,363,708,152</u>	<u>633,557,883,132</u>

27. PRODUCTION COST BY NATURE:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Raw materials and merchandise	136,160,787,930	171,309,395,945	442,569,209,720	490,689,954,538
Labor costs	54,215,497,467	92,396,425,953	263,256,790,994	262,645,112,130
Depreciation and amortization	12,836,872,293	12,098,255,274	38,349,338,641	35,918,963,500
External services expenses	38,592,962,108	35,884,425,481	109,555,694,118	104,518,777,918
Other expenses	60,315,853,937	44,034,565,726	139,888,001,750	116,450,564,517
Provision for doubtful debts	(1,100,054,529)	(949,061,004)	(3,736,706,861)	1,282,869,289
	<u>301,021,919,206</u>	<u>354,774,007,375</u>	<u>989,882,328,362</u>	<u>1,011,506,241,892</u>

28. FINANCIAL INCOME:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Interest income	5,153,756,712	2,703,352,849	13,636,885,818	7,235,875,687
Foreign exchange gains	3,934,319,774	665,812,003	4,659,354,855	1,495,019,531
	<u>9,088,076,486</u>	<u>3,369,164,852</u>	<u>18,296,240,673</u>	<u>8,730,895,218</u>

29. FINANCIAL EXPENSES:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Interest expenses	1,339,973,239	817,753,000	2,844,596,315	3,071,197,275
Provision for diminution in value of investment in other entity	-	2,000,000,000	-	2,000,000,000
Payment discount	1,792,278,159	1,864,858,969	5,654,978,423	5,878,105,463
Foreign exchange loss	958,229,503	60,211,977	2,287,385,996	1,781,972,429
	<u>4,090,480,901</u>	<u>4,742,823,946</u>	<u>10,786,960,734</u>	<u>12,731,275,167</u>

30. SELLING EXPENSES:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Labor cost	26,084,573,493	56,901,306,316	153,145,497,670	161,026,748,256
Depreciation	756,136,526	846,792,854	2,360,111,780	2,380,777,068
External services expenses	16,655,992,214	14,333,472,138	45,038,763,872	41,263,322,344
Others	44,599,663,124	38,535,976,581	113,285,989,557	99,309,397,584
	<u>88,096,365,357</u>	<u>110,617,547,889</u>	<u>313,830,362,879</u>	<u>303,980,245,252</u>

31. GENERAL AND ADMINISTRATION EXPENSES:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Labor cost	3,140,915,751	11,923,851,270	38,283,871,402	34,698,976,355
Depreciation	2,173,293,577	2,472,694,994	6,767,526,686	7,487,882,515
External services expenses	4,510,940,538	2,865,109,028	12,367,414,245	8,288,028,468
Others	14,846,162,524	4,656,920,302	24,140,774,711	15,127,694,456
(Reversal of provision) provision	(1,100,054,529)	(949,061,004)	(3,736,706,861)	1,282,869,289
	<u>23,571,257,861</u>	<u>20,969,514,590</u>	<u>77,822,880,183</u>	<u>66,885,451,083</u>

32. CORPORATE INCOME TAX EXPENSE:

	Third quarter of 2025	Third quarter of 2024	Accumulated nine months of 2025	Accumulated nine months of 2024
	VND	VND	VND	VND
Current corporate income tax expense	11,910,845,417	13,478,655,299	43,362,755,692	40,285,244,758
Deferred income tax income/ (expense)	(351,835,610)	(109,080,084)	(503,089,343)	(511,963,963)
	<u>11,559,009,807</u>	<u>13,369,575,215</u>	<u>42,859,666,349</u>	<u>39,773,280,795</u>




Pham Thi Thanh May
Preparer



Do Huy Phuong
Chief Accountant




Pham Thi Thanh Huong
General Director
October, 27th, 2025